儿童期诊断肥厚型心肌病患者的左室收缩功能障碍:SHaRe注册研究
基于国际多中心SHaRe注册研究,比较儿童期(<18岁)与成人期诊断肥厚型心肌病(HCM)患者左室收缩功能障碍(LVSD)的患病率、预测因素和预后。儿童期诊断HCM患者LVSD总体患病率14.7%,高于成人组的8.7%,且发生年龄更早;
要点
- 儿童期诊断HCM患者LVSD总体患病率14.7%,高于成人诊断者的8.7%。
- 儿童期诊断者发生LVSD的中位年龄为32.6岁,早于成人诊断者的57.2岁。
核心结论
- 儿童期诊断HCM患者终生发生LVSD风险显著更高,且LVSD出现早于成人期诊断患者。
- 无论HCM或LVSD诊断年龄,合并LVSD预后均差,需加强LVSD监测,尤其在儿童HCM向成人医疗过渡期。
研究设计与样本
- 国际多中心SHaRe注册研究数据分析,纳入1010例儿童期(<18岁)诊断HCM患者,与6741例成人期诊断HCM患者比较。
- LVSD定义为超声心动图报告左室射血分数<50%。
- 预后评估采用死亡、心脏移植和左室辅助装置植入的复合终点。
- 采用Cox比例风险模型评估 incident LVSD 的预测因素及LVSD后的预后。
主要发现
- 儿童期诊断HCM队列诊断中位年龄12.7岁(IQR 8.0-15.3),女性393例(36%)。
- 初始评估时56例(5.5%)存在LVSD,中位随访5.5年间92例(9.1%)发生 incident LVSD,总体LVSD患病率14.7%,成人诊断组为8.7%。
- 儿童期诊断队列 incident LVSD 中位年龄32.6岁(IQR 21.3-41.6),成人诊断队列为57.2岁(IQR 47.3-66.5)。
临床怎么用
- 对儿童期诊断HCM患者应加强LVSD监测,尤其关注诊断年龄<12岁、男性、携带致病性肌节蛋白变异、既往室间隔减容治疗及初始LVEF较低者。
- 儿童HCM患者向成人医疗过渡期间需持续警惕LVSD发生,LVEF<35%或女性患者预后更差,应密切随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The development of left ventricular systolic dysfunction (LVSD) in hypertrophic cardiomyopathy (HCM) is rare but serious and associated with poor outcomes in adults. Little is known about the prevalence, predictors, and prognosis of LVSD in patients diagnosed with HCM as children. METHODS: Data from patients with HCM in the international, multicenter SHaRe (Sarcomeric Human Cardiomyopathy Registry) were analyzed. LVSD was defined as left ventricular ejection fraction <50% on echocardiographic reports. Prognosis was assessed by a composite of death, cardiac transplantation, and left ventricular assist device implantation. Predictors of developing incident LVSD and subsequent prognosis with LVSD were assessed using Cox proportional hazards models. RESULTS: We studied 1010 patients diagnosed with HCM during childhood (<18 years of age) and compared them with 6741 patients with HCM diagnosed as adults. In the pediatric HCM cohort, median age at HCM diagnosis was 12.7 years (interquartile range, 8.0-15.3), and 393 (36%) patients were female. At initial SHaRe site evaluation, 56 (5.5%) patients with childhood-diagnosed HCM had prevalent LVSD, and 92 (9.1%) developed incident LVSD during a median follow-up of 5.5 years. Overall LVSD prevalence was 14.7% compared with 8.7% in patients with adult-diagnosed HCM. Median age at incident LVSD was 32.6 years (interquartile range, 21.3-41.6) for the pediatric cohort and 57.2 years (interquartile range, 47.3-66.5) for the adult cohort. Predictors of developing incident LVSD in childhood-diagnosed HCM included age <12 years at HCM diagnosis (hazard ratio [HR], 1.72 [CI, 1.13-2.62), male sex (HR, 3.1 [CI, 1.88-5.2), carrying a pathogenic sarcomere variant (HR, 2.19 [CI, 1.08-4.4]), previous septal reduction therapy (HR, 2.34 [CI, 1.42-3.9]), and lower initial left ventricular ejection fraction (HR, 1.53 [CI, 1.38-1.69] per 5% decrease). Forty percent of patients with LVSD and HCM diagnosed during childhood met the composite outcome, with higher rates in female participants (HR, 2.60 [CI, 1.41-4.78]) and patients with a left ventricular ejection fraction <35% (HR, 3.76 [2.16-6.52]). CONCLUSIONS: Patients with childhood-diagnosed HCM have a significantly higher lifetime risk of developing LVSD, and LVSD emerges earlier than for patients with adult-diagnosed HCM. Regardless of age at diagnosis with HCM or LVSD, the prognosis with LVSD is poor, warranting careful surveillance for LVSD, especially as children with HCM transition to adult care.
引用
- Abou Alaiwi S, Roston TM, Marstrand P, et al. Left Ventricular Systolic Dysfunction in Patients Diagnosed With Hypertrophic Cardiomyopathy During Childhood: Insights From the SHaRe Registry. Circulation. 2023. PMID: 37226762. doi:10.1161/CIRCULATIONAHA.122.062517
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。